A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Orciprenaline
Trilostane
The therapeutic efficacy of Trilostane can be decreased when used in combination with Tubocurarine.
Orciprenaline
Fosphenytoin
The therapeutic efficacy of Fosphenytoin can be decreased when used in combination with Tubocurarine.
Orciprenaline
Azosemide
Azosemide may decrease the neuromuscular blocking activities of Tubocurarine.
Orciprenaline
Piretanide
Piretanide may decrease the neuromuscular blocking activities of Tubocurarine.
Orciprenaline
Lithium cation
The risk or severity of adverse effects can be increased when Tubocurarine is combined with Lithium cation.
Orciprenaline
Lemborexant
The risk or severity of adverse effects can be increased when Tubocurarine is combined with Lemborexant.
Orciprenaline
JNJ-26489112
The risk or severity of adverse effects can be increased when Tubocurarine is combined with JNJ-26489112.
Orciprenaline
Solriamfetol
The risk or severity of adverse effects can be increased when Tubocurarine is combined with Solriamfetol.
Orciprenaline
Bentazepam
The risk or severity of adverse effects can be increased when Tubocurarine is combined with Bentazepam.
Orciprenaline
Pyrazolam
The risk or severity of adverse effects can be increased when Tubocurarine is combined with Pyrazolam.
Orciprenaline
Cinazepam
The risk or severity of adverse effects can be increased when Tubocurarine is combined with Cinazepam.
Orciprenaline
Oxazepam acetate
The risk or severity of adverse effects can be increased when Tubocurarine is combined with Oxazepam acetate.
Orciprenaline
Perphenazine enanthate
The risk or severity of adverse effects can be increased when Tubocurarine is combined with Perphenazine enanthate.
Orciprenaline
Eslicarbazepine
The risk or severity of adverse effects can be increased when Tubocurarine is combined with Eslicarbazepine.
Orciprenaline
Lithium carbonate
The risk or severity of adverse effects can be increased when Tubocurarine is combined with Lithium carbonate.
Orciprenaline
Aripiprazole lauroxil
The risk or severity of adverse effects can be increased when Tubocurarine is combined with Aripiprazole lauroxil.
Orciprenaline
Cannabidivarin
The risk or severity of adverse effects can be increased when Tubocurarine is combined with Cannabidivarin.
Orciprenaline
Nordazepam
The risk or severity of adverse effects can be increased when Tubocurarine is combined with Nordazepam.
Orciprenaline
5-methoxy-N,N-dimethyltryptamine
The risk or severity of adverse effects can be increased when Tubocurarine is combined with 5-methoxy-N,N-dimethyltryptamine.
Orciprenaline
MRK-409
The risk or severity of adverse effects can be increased when Tubocurarine is combined with MRK-409.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3